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OBJECTIVES The objective of this study was to test the hypothesis that the intracoronary administration of
a direct donor of nitric oxide is a safe and effective method to treat impaired blood flow
(no-reflow phenomenon) that occurs during percutaneous transluminal coronary interven-
tions (PTCI).
BACKGROUND The absence of blood flow or decreased blood flow in a coronary artery following PTCI
despite the presence of a patent epicardial vessel or graft is designated “no-reflow” or
“impaired flow.” This alteration in blood flow is a serious complication of percutaneous
revascularization strategies that results in an increased incidence of morbidity, myocardial
infarction and mortality.
METHODS Nineteen consecutive patients undergoing standard percutaneous revascularization procedures
complicated by either no-reflow or impaired flow that received intracoronary nitroprusside
treatment were studied. One patient had two procedures performed on two separate grafts on
two successive days. Interventions were performed on either saphenous vein grafts or native
vessels and utilized angioplasty, stent deployment or rotational atherectomy strategies.
Following interventions that were associated with impaired flow, varying total doses (of
nitroprusside 50 to 1,000 mg) were administered into the coronary artery or saphenous vein
graft. The angiographic archives before and after intracoronary administration of nitroprus-
side were analyzed for TIMI grade flow and a frame count method was used to quantitate
blood flow velocity.
RESULTS Following a PTCI that resulted in either no-reflow or impaired flow, nitroprusside (median
dose 200 mg) was found to lead to a highly significant and rapid improvement in both
angiographic flow (p , 0.01 compared with pretreatment angiogram) and blood flow velocity
(p , 0.01 compared with pretreatment angiogram). No significant hypotension or other
adverse clinical events were associated with nitroprusside administration.
CONCLUSIONS The direct nitric oxide donor nitroprusside is an effective, safe treatment of impaired blood
flow and no-reflow associated with PTCI. The use of nitroprusside to treat syndromes
secondary to microvascular dysfunction may provide a novel therapeutic strategy for treating
no-reflow or impaired blood flow following percutaneous interventions. (J Am Coll Cardiol
2001;37:1335–43) © 2001 by the American College of Cardiology
The “no-reflow” phenomenon has been conventionally de-
scribed as the persistence of abnormally slow myocardial
blood flow in the absence of an angiographically significant
coronary artery or vein graft obstruction (1). The phenom-
enon encompasses states of no flow as well as significantly
impaired blood flow. Originally observed in animal models
of myocardial infarction, the phenomenon has been ob-
served clinically after percutaneous coronary interventions
(PTCI) (1,2). Patients who experience no-reflow or im-
paired blood flow following PTCI have an increased risk of
subsequent myocardial infarction and death (1,2) and can
experience increased morbidity during the procedure.
An efficacious treatment of compromised blood flow
associated with PTCI remains problematic. Several ap-
proaches to the problem have been published, including
intracoronary or intragraft injections of verapamil, nitro-
glycerin, diltiazem, urokinase, abciximab, intra-aortic bal-
loon pumps and papaverine (1–7) or high-velocity injections
of intracoronary adenosine (8). Despite some positive re-
sults, no-reflow or impaired flow remains a serious problem
for PTCI, especially when revascularizing saphenous vein
grafts.
The exact mechanisms underlying this clinical condition
are not known, but more recent evidence suggests that
no-reflow or slow flow is due to dysfunction of the micro-
circulation at the level of the resistance arterioles. To this
end, the no-reflow phenomenon may stem from microvas-
cular dysfunction and vasospasm in this vascular bed due to
platelet-derived vasoconstrictors and/or systemic and local
release of agents such as endothelin that induce vasospasm.
Alternatively, antegrade resistance to arteriolar flow may be
compromised by mechanical obstruction from emboli orig-
inating from material dislodged from the target vessel.
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Nitric oxide is an endothelium-derived compound that
has multiple vascular functions, including vasodilation, in-
hibition of platelet adhesion and anti-inflammatory activity.
Nitric oxide is a potent vasodilator in the resistance arterio-
lar circulation (9) and plays a significant role in the control
of coronary blood flow through the microcirculation (10).
Although nitrates have traditionally been used as donors of
nitric oxide to maximally dilate coronary arteries, significant
differences between epicardial arteries and resistance arte-
rioles have been described with respect to the metabolism of
exogenous nitrates (11). Metabolism of nitroglycerin by the
vascular wall is necessary to derive nitric oxide. However,
resistance arterioles are unable to metabolize nitroglycerin
to nitric oxide as do large nonresistance vessels (12), and
nitroglycerin is relatively less efficacious in eliciting dilation
in microvessels compared with large, epicardial vessels. On
the other hand, nitroprusside (NTP) is a direct donor of
nitric oxide and is reported to require no intracellular
metabolism to derive nitric oxide (13). Therefore, we
hypothesized that NTP may be efficacious for the treatment
of no-reflow primarily through its action as a nitric oxide
donor and vasodilation of microvessels. This study reports
our initial clinical experience in 20 consecutive percutaneous
coronary interventions complicated by no-reflow phenom-
enon where intracoronary NTP, as a direct nitric oxide
donor, was administered.
METHODS
Patient population. The interventional procedure data-
bases at the Nashville Veterans Administration Medical
Center (VAMC) and Vanderbilt University Medical Center
(VUMC) were screened for cases performed between July
1997 and May 1998 with occurrence of no-reflow or
impaired flow and the use of intracoronary NTP. Screening
these databases identified 20 procedures where 19 patients
had received intracoronary NTP for no-reflow. One patient
had two procedures done on separate grafts on successive
days. To avoid selection bias, consecutive patient cases were
analyzed. The cineangiograms or digital archives were
subsequently reviewed to confirm the absence of dissection,
thrombosis or macroembolization as the explanation for
slow coronary flow.
For each of these cases, supplemental demographic and
procedural data were recorded. Demographic data included
date of birth, gender and race. Preprocedural factors col-
lected were diabetes (insulin-dependent or noninsulin-
dependent), prior coronary artery bypass grafting and pro-
cedure indication (including angina, acute myocardial
infarction, postinfarction angina and silent ischemia). Pro-
cedure devices used and pharmacological interventions
(drug, delivery, time of delivery and dosage) were recorded.
Angiographic assessment. Impaired blood flow was de-
fined as a reduction in antegrade blood flow (,Thrombol-
ysis In Myocardial Infarction [TIMI] III, thrombolysis in
myocardial infarction) following PTCI that was not second-
ary to abrupt closure, spasm or significant stenosis of the
original target lesion (1). All cineangiograms or digital
archives were taken at a speed of 15 frames/s. Films from
the VAMC were reviewed on the digital system (Camtron-
ics Medical Systems, Hartland, Wisconsin) with its built-in
frame counter (also at 15 frames/s) whereas films from
VUMC were reviewed on a cineangiogram projector with a
frame counter. At least two angiographers assessed each
angiogram for modified TIMI grade flow (with the addi-
tional division of TIMI II flow into “slow” and “fast” grades)
and for quantitative frame counts to maximal opacification
of distal landmarks. The two readers each graded the flows
as TIMI-0, TIMI-1, TIMI-2 slow, TIMI-2 fast or TIMI-3
flow. The results were averaged using 0, 1, 2, 2.5 and 3,
respectively. Frame counts were divided into measured
distances for calculation of absolute flow velocities in cm/s.
The vessel length was measured with calipers calibrated
from the known guide catheter diameter. The least fore-
shortened view was selected for the cine pairs to measure
frame counts before and after NTP administration. Observ-
ers assessed flow at baseline prior to intervention, before and
after intracoronary or intragraft NTP injections and at the
completion of the intervention. The percent change in
coronary flow velocity was determined by the formula:
% Change in VF5
@~postnitroprusside VF) 2 (prenitroprusside VF)]
(prenitroprusside VF)
3 100
where VF 5 flow velocity measured in cm/s.
Data were also normalized according to the following
method: The VF at initial, during no-reflow, post-NTP and
at the final angiogram were divided by the maximal VF
measured at any point during the study. The purpose of
normalization was to eliminate variance between the abso-
lute flow rates observed between patients so that each
patient would receive equal weighting in the analysis.
The American College of Cardiology/American Heart
Association lesion morphology classification was collected.
Pre-and postintervention visual percent stenoses were esti-
mated as well as whether the no-reflow was transient or
sustained at the end of the procedure.
Hemodynamic analysis. Patients were continuously mon-
itored during all procedures. Heart rates and blood pressures
recorded before and after administration of NTP were
determined. The data regarding any effects of intravessel
Abbreviations and Acronyms
NTP 5 nitroprusside
PTCI 5 percutaneous coronary interventions
TIMI 5 Thrombolysis In Myocardial Infarction
VAMC 5 Veterans Administration Medical Center
VF 5 flow velocity
VUMC 5 Vanderbilt University Medical Center
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NTP were analyzed to ascertain adverse clinical effects on
cardiac hemodynamics.
Management of impaired flow and no flow. All patients
received intravessel NTP for treatment of both no-reflow
and impaired flow at a dose of at least 50 mg given distal to
the target lesion via the angioplasty balloon lumen or,
alternatively, through the guide catheter. In general, drug
was delivered distal to where there was no apparent angio-
graphic flow via the angioplasty balloon lumen. Drug could
be delivered more proximally in slow states. Twenty-seven
doses were administered through the guiding catheter; 16
were given distally. Four patients also received other phar-
macological interventions, including intracoronary adeno-
sine and/or verapamil, for refractory no-reflow.
The time from cineangiogram documenting no-reflow to
NTP dose was a median of 5 min (range 1 to 20 min, mean
7.3 min) and the time from NTP to follow-up cineangio-
gram was a median of 2 min (range 0.5 to 31 min, mean
3.9 min). The total time between the cineangiogram doc-
umenting no-reflow and the post-NTP angiogram was a
median of 7 min.
Statistical methods. Discrete variables are presented as
percentages and continuous variables as means with stan-
dard deviations. The normalized coronary flow velocities
were analyzed on initial angiogram, during no-reflow,
post-NTP and at the final angiogram.
The normalized flow velocity effects of NTP on impaired
flow (no-reflow) and TIMI flow grades were compared
using repeated-measures analysis of variance. The subsets of
patients with greater than TIMI 0 and TIMI 1 flow were
also analyzed to help separate the effects of improvement in
coronary flow velocity due to treatment of no-reflow or
impaired flow with NTP from that secondary to treatment
of the initial total or subtotal occlusion.
Multivariate logistic regression analysis was performed to
determine if the NTP dose, delivery method, other medi-
cations and time from NTP dose to postcineangiogram
were significant independent predictors of the observed
change in normalized coronary flow velocities.
Statistical significance was defined as p , 0.05. Statistical
analyses were performed using the SPSS (Chicago, Illinois)
program.
RESULTS
Study population characteristics. The clinical and proce-
dural characteristics of the patients in whom NTP was
administered for no-reflow are shown in Table 1. The target
lesion was in a native vessel in 60% of the procedures
analyzed, whereas 40% of the procedures were in saphenous
vein grafts. Three patients were treated for impaired blood
flow following PTCI during an acute myocardial infarction
(15%), with the remainder undergoing revascularization for
stable angina, unstable angina or postinfarction angina.
Most of the revascularization procedures were primary stent
deployment (70%). In 16 out of the 20 procedures, the
patients received prophylactic abciximab therapy. No pa-
tient received “bail-out” abciximab.
NTP administration. The dosing characteristics for either
intracoronary or intragraft administration of NTP are sum-
marized in Table 2. The median injection dose was 200 mg
of drug with a mean of 2.2 injections per patient for a
total of 43 injections. In the majority of cases (63%), drug
was given via the guiding catheter with the remainder
given distally through the lumen of the angioplasty
balloon.
Effects of NTP on no-flow and impaired flow. PERCENT
CHANGE IN CORONARY FLOW VELOCITY COMPARING PRE-
AND POST-NTP TREATMENT. The results of intravascular
NTP administration on coronary blood flow velocity (VF,
cm/s) (measured using a frame count analysis method; see
methods section) were analyzed as the percent change in VF
Table 1. Baseline Clinical and Procedural Characteristics of
Patients Receiving Intravascular Nitroprusside
Characteristic Rate
Gender (% male) 17 (90%)
Age (mean 6 SD) 65.6 (610.5)
Comorbid conditions
Diabetes 3 (15%)
Previous CABG 9 (45%)
Indication
Stable angina 3 (15%)
Unstable angina 11 (55%)
Acute MI 3 (15%)
Postinfarct 3 (15%)
Devices used
PTCA only 1 (5%)
Stent 14 (70%)
Rotoblator and stent 3 (15%)
TEC, Stent, PTCA 2 (10%)
Lesion location
Saphenous vein graft 9 (45%)
Left anterior descending 7 (35%)
Circumflex 4 (20%)
Lesion class
Type A 0
Type B3 1 (5%)
Type B4 1 (5%)
Type C 18 (90%)
Preprocedural angiographic appearance of thrombus* 14 (70%)
TIMI flow grade on initial cineangiogram
TIMI 0 4 (20%)
TIMI 1 3 (15%)
TIMI 2 4 (20%)
TIMI 2.5 3 (15%)
TIMI 3 6 (30%)
TIMI flow grade on final cineangiogram
TIMI 0 1 (5%)
TIMI 1 1 (5%)
TIMI 2 2 (10%)
TIMI 2.5 1 (5%)
TIMI 3 15 (75%)
Prophylactic ReoPro use 16 (80%)
*Preprocedural thrombus was defined as discrete intraluminal filling defect, contrast
staining, or haze in the target vessel or at the site of the target lesion.
CABG 5 coronary artery bypass graft; MI 5 myocardial infarction; PTCA 5
percutaneous transluminal coronary angiography; TEC 5 transluminal extraction
catheter; TIMI 5 Thrombolysis In Myocardial Infarction.
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from no-reflow to post-NTP treatment for each vessel
treated (Fig. 1). In 14 of the 19 patients, there was a positive
response to NTP, whereas 5 of the 19 (25%) were nonre-
sponders (Fig. 1). Nitroprusside resulted in a mean 47%
(95% CI: 28% to 67%; p 5 0.003) improvement in coronary
flow velocity (Table 3). In the analysis of the data examining
each target vessel injection there was a mean 43% (95% CI:
21% to 65%; p 5 0.002) improvement in coronary flow
velocity (Table 3).
The effect of NTP on blood flow velocity was not
significantly different between graft versus native vessel,
atherectomy versus nonatherectomy procedure, or prepro-
cedural angiographic evidence of thrombus being present
versus absent by multivariate logistic regression analysis.
NORMALIZED CORONARY BLOOD FLOW VELOCITY AT THE
INITIAL ANGIOGRAM, THE ANGIOGRAM DURING IMPAIRED
FLOW, THE ANGIOGRAM POST-NTP AND THE FINAL ANGIO-
GRAM. The absolute coronary flow velocity was determined
at the initial angiogram, the angiogram during impaired
flow (no-reflow), the angiogram taken post-NTP and at the
final angiogram. Because of variability in the absolute flow
rates between patients, the VF for each patient was normal-
ized by dividing the four observed flow velocities by the
maximal velocity observed at any point in the procedure.
Twelve of nineteen patients had maximal flow at the final
angiogram, six of nineteen had maximal flow at the post-
NTP angiogram, and one of twenty had maximal flow at the
initial angiogram. Normalization allowed expression of the
flow velocity as a ratio between 0 and 1 for each time point
in each procedure.
Nitroprusside at the final angiogram had elicited a sig-
nificant improvement in VF by angiographic analysis that
was highly significant compared with flow during the initial
angiogram and the state of impaired flow or no-reflow (Fig.
2, solid bars; n 5 19): initial versus post-NTP, p 5 0.04;
initial versus final, p 5 0.003; impaired flow versus final,
p 5 0.003; post-NTP versus final, p 5 0.017.
Figure 2 (hatched bars; n 5 15) also presents the data
excluding the four patients with no flow at the initial
angiogram to separate the possible confounding effect of
treatment of the initial lesion on observed flow. There was
a significant improvement in VF by angiographic analysis
following NTP at the final angiogram compared with initial
angiogram and the no-reflow angiogram: initial versus final,
p 5 0.05; impaired flow versus post-NTP, p 5 0.043;
impaired flow versus final, p 5 0.016. Data were analyzed
using analysis of variance for repeated measures.
Of the 19 consecutive patients, one had two procedures
done on different saphenous vein grafts (graft to posterior
descending artery and graft to obtuse marginal artery) on
two consecutive days. We therefore submitted these data to
an identical analysis, except as 20 consecutive procedures.
As with the per-patient analysis, the per-procedure analysis
showed that NTP at the final angiogram had elicited a
significant improvement in VF that was highly significant
compared to flow during the initial angiogram, flow during
the impaired flow or no-reflow state and post-NTP (data
not shown).
TIMI FLOW RATE ANALYSIS. Analysis of TIMI flow rates
showed a significantly enhanced TIMI grade flow compar-
ing no-reflow to the angiogram post-NTP administration
(Fig. 3). Examination of TIMI flow rates at the initial
angiogram, impaired flow angiogram (no-flow), post-NTP
angiogram and final angiogram demonstrated the con-
founding effect of the initial lesion severity on observed
Figure 1. Mean percent change in normalized cineangiographic coronary
flow per patient treated for percutaneous coronary intervention-associated
no flow or impaired blood flow with intravascular nitroprusside. The
normalized coronary blood flow was calculated as described in the methods.
Table 2. Intravascular Nitroprusside Administration
Nitroprusside injections per Mean 5 2.2; SD 6 1.6
patient Median 5 2
Range 5 1–7
Nitroprusside dose per injection* Mean 5 207 mg; SD 6 178 mg
Median 5 200 mg
Range 5 50–1,000 mg
Total nitroprusside dose per Mean 5 435 mg; SD 6 419 mg
patient Median 5 300 mg
Range 5 50–1,400 mg
Time from dosage to post- Mean 5 3.9 min; SD 6 5.5 min
cineangiogram Median 5 2 min
Range 5 0.5–31 min
Route of administration
Via guide catheter 27 (63%)
Via distal balloon delivery† 16 (37%)
Data regarding the administration of intracoronary or intragraft nitroprusside.
*Nitroprusside dose per injection was defined as the total quantity of intracoronary
nitroprusside administered between the cineangiogram documenting no-reflow and
the subsequent post-nitroprusside administration cineangiogram. †Distal delivery is
defined as the delivery of drug through the wire lumen of an interventional device
placed distal to the target lesion in the vessel.
SD 5 standard deviation.
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TIMI flow, as seven patients had either TIMI 0 or TIMI 1
flow on the initial angiogram. Therefore data are presented
with and without four patients who had TIMI 0 flow at the
initial angiogram (Fig. 3) and also as only those patients
with TIMI 2 or higher flow at the initial angiogram (Fig. 4).
In the analysis of all 19 patients, NTP elicited a signifi-
cant increase in TIMI grade flow (Fig. 3, solid bars): initial
versus post-NTP, p 5 0.013; initial versus final, p 5 0.011;
no-reflow versus post-NP, p 5 0.001; no-reflow versus
final, p 5 0.001.
In the analysis that excluded procedures with an initial
TIMI grade 0 flow, NTP significantly improved TIMI
grade blood flow (Fig. 3, hatched bars; n 5 15): no-reflow
versus post-NTP, p 5 0.004; no-reflow versus final, p 5
0.009. Data were analyzed using analysis of variance for
repeated measures.
Figure 2. Normalized flow velocity of coronary blood flow at the initial cineangiogram of the procedure, with impaired flow, immediately postintracoronary
nitroprusside (NTP) administration and at the final cineangiogram of the procedure. The data were normalized for the maximal flow velocity observed at
any point in the procedure, as described in the methods section. The results are expressed with (solid bars) and without four patients (hatched bars) that
had total occlusion and Thrombolysis In Myocardial Infarction (TIMI) 0 flow on the initial cineangiogram of the procedure. The numbers represent the
mean value 6 the 95% confidence interval (error bars). There was a significant increase in coronary flow velocity following nitroprusside administration
(solid bars) (see text for statistical data). In the analysis that excluded procedures with TIMI 0 flow at the initial angiogram (n 5 15), nitroprusside
administration significantly increased coronary flow velocity (hatched bars) (see text for statistical data).
Table 3. Change in Cineangiographic Flow with Intravascular Nitroprusside Administration
Outcome
Mean
(Percent)
SD
(Percent) 95% CI
p
Value*
Percent change in flow per injection 143% 673 60.22 p 5 0.002
Percent change in flow per procedure 147% 644 60.19 p 5 0.003
Percent change in flow for native vessels 136% 642 60.24 p 5 0.037
Percent change in flow for vein grafts 176% 643 60.30 p 5 0.023
Percent change in flow in presence of thrombus 144% 646 60.25 p 5 0.031
*p values were derived using a two-tailed paired sample t test.
Cineangiographic data for patients receiving intracoronary nitroprusside. The percent change in coronary flow velocity was
determined by the formula:
% change in VF 5 [(postnitroprusside VF) 2 (prenitroprusside VF)] 4 (prenitroprusside VF)
where VF 5 flow velocity measured in cm/sec. Data were analyzed on the basis of per injection as well as per patient. The
subgroups of native vessels, saphenous vein grafts or angiographic evidence of thrombus were analyzed.
CI 5 confidence interval; SD 5 standard deviation.
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Similar to the normalized flow velocity analysis, we
submitted the data to both a per-patient analysis and a
per-procedure analysis. Nitroprusside at the final angiogram
had elicited a significant improvement in TIMI grade flow
that was highly significant compared with flow during the
initial angiogram, flow during the impaired flow or no-
reflow state, and post-NTP (data not shown).
Data were analyzed in those patients with TIMI 2 or
higher flow at the initial angiogram (Fig. 4). Nitroprusside
had an extremely significant beneficial effect on reestablish-
ing blood flow following the “no-reflow” or impaired flow
state (impaired flow compared to post-NTP and final
angiograms for patients with $TIMI 2 grade flow at the
initial angiogram, p 5 0.001 and 0.008, respectively). There
was a significant decrease in TIMI flow between the initial
angiogram and the impaired, no-reflow state (p 5 0.03).
ALTERNATIVE THERAPIES. Four patients received another
pharmacologic agent for impaired blood flow in addition to
intracoronary NTP, excluding intracoronary nitroglycerin.
Although this sample size of additional agents is too small
to draw definitive conclusions, they did not have a signifi-
cant, independent effect on coronary flow velocity in mul-
tivariate logistic regression analysis. Similarly, dose and site
of delivery did not have a significant independent relation-
ship with change in normalized coronary flow velocity.
Hemodynamic effects of NTP. Analysis of the hemody-
namic data showed no evidence that NTP significantly
altered patient blood pressure and heart rate at the doses
used (50 to 200 mg per injection) (Table 4). The clinical
dose of NTP used was operator-determined on the basis of
blood pressure and volume status of the patient. The
hemodynamic responses of all patients, together with blood
pressures and heart rates, were collected at least 10 min
before NTP injection and no later than 30 min postinjec-
tion.
DISCUSSION
Reduced or absent blood flow associated with PTCI is a
common and serious complication of percutaneous revascu-
larization strategies, especially those associated with older
saphenous vein grafts. Either impaired flow or the absence
of flow has been demonstrated to be associated with an
increased incidence of myocardial infarction and death (1).
Our results suggest a novel therapeutic strategy to treat
impaired flow based upon the known actions of nitric oxide
on the microvasculature. The principal finding reported in
this study was that intravascular administration of a direct
donor of nitric oxide markedly decreased the severity of
clinically significant, refractory no-reflow associated with
percutaneous revascularization.
Figure 3. Thrombolysis In Myocardial Infarction (TIMI) grade flow at the initial cineangiogram of the procedure, with impaired flow, immediately
postintracoronary nitroprusside (NTP) administration and at the final cineangiogram of the procedure. The results are expressed with and without four
patients (hatched bars)) that had total occlusion and TIMI 0 flow on the initial cineangiogram of the procedure. Data are expressed as the mean value 6
the 95% confidence interval (error bars). Nitroprusside administration had a significant beneficial effect on reestablishing blood flow in both methods of
analysis (see text for statistical data).
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The treatment of altered blood flow associated with
PTCI has primarily utilized direct smooth-muscle vasodi-
lators with varied mechanisms of action, including adeno-
sine, nitroglycerin and calcium antagonists. Kaplan et al. (6),
in a study of 36 saphenous vein grafts, found that verapamil
was an effective therapy for no-reflow whereas nitroglycerin
was not effective in reestablishing flow. Piana et al. (2) also
reported that verapamil was effective in improving no-reflow
in 89% of cases. Verapamil has also been reported to exert a
beneficial effect on microvascular function in low reflow
states and enhance myocardial blood flow following a
myocardial infarction (14). More recently, high velocity
boluses of intracoronary adenosine have been reported to
effectively treat no-reflow following vein graft stenting (8).
Coronary blood flow is primarily determined by the
resistance-sized arterioles ,150 microns in diameter (15).
Furthermore, significant differences have been reported
between vasomotion of large versus small, resistance-sized
arterioles (16). Although the pathophysiology of no-reflow
is not exactly known, it is characterized by the failure of
perfusion of the coronary microcirculation. Current evi-
dence suggests that no-reflow may represent the complex
interaction between abnormal vasomotion of microvessels
associated with preexisting atherosclerosis (17–19) and en-
dothelial cell dysfunction in the microcirculation (20).
Compromised coronary blood flow in the setting of this
underlying pathophysiology may be exacerbated by the
release of vasoactive agents from conduit vessels following
barotrauma or debulking, activation of inflammatory cells
and “showering” of obstructive emboli. Nitric oxide is
endogenously produced by the vascular endothelium and
has multiple biological actions potentially relevant to no-
reflow, including its ability to act as a potent vasodilator,
anti-inflammatory agent, and antiplatelet agent (18,21–23).
Thus, NTP, a direct nitric oxide donor, may importantly
Figure 4. Thrombolysis In Myocardial Infarction (TIMI) grade flow at the initial cineangiogram of the procedure, with impaired flow (no-reflow),
immediately postintracoronary nitroprusside (NTP) administration and at the final cineangiogram of the procedure for 13 patients with $TIMI II flow
on the initial angiogram. Results are expressed as the mean value 6 the 95% confidence interval (error bars). Nitroprusside had an extremely significant
beneficial effect on re-establishing blood flow following the “no-reflow” or impaired flow state (*impaired flow compared with postnitroprusside and final
angiograms for patients with $TIMI II grade flow at the initial angiogram, p 5 0.001 and 0.008, respectively). There was a significant decrease in TIMI
flow between the initial angiogram and the impaired no-reflow state (†p 5 0.03).
Table 4. Hemodynamic Effects of Intravascular
Nitroprusside Administration
Systolic pressure
Predosage 139 mm Hg
Postdosage 126 mm Hg
Diastolic pressure
Predosage 72 mm Hg
Postdosage 70 mm Hg
Heart rate
Predosage 71 beats/min
Postdosage 74 beats/min
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alter the pathophysiology underlying the no-reflow phe-
nomenon. Furthermore, nitric oxide could positively affect
latent collaterals or collateral blood flow by eliciting vaso-
dilation (24) or inhibit platelet aggregation in the vascular
bed distal to the target lesion.
The central hypothesis tested here, to ascertain if nitric
oxide is an effective treatment of no flow or impaired blood
flow associated with PTCI, was founded upon previous
work comparing the actions of nitroglycerin and NTP in
coronary resistance microvessels. Prior studies with intra-
coronary nitroglycerin may have failed to demonstrate
efficacy of the compound as an effective treatment of
no-reflow because of the relative inability of resistance
arterioles to metabolize nitroglycerin to a nitric oxide or
nitrosyl product. This is in contradistinction to the potent
vasodilator effects of nitroglycerin on large epicardial arter-
ies. Experimental results have demonstrated that nitroglyc-
erin is a less efficacious dilator of coronary arterioles
,100 mM in diameter (17). Therefore, NTP offers an
advantage by directly delivering nitric oxide without requir-
ing metabolic processing by the microvascular smooth
muscle cells. Compounds with lower oxidation states, such
as NTP, release nitric oxide nonenzymatically (11) and offer
an advantage over compounds that require enzymatic con-
version. An alternative explanation is that the relative
efficacy of nitroglycerin as a vasodilator of resistance arte-
rioles may be impaired by autoregulatory effects character-
istic of the microcirculation that compensates for
nitroglycerin-induced vasodilation (25,26).
Study limitations. This initial clinical observation has
several limitations. First, the use of intracoronary NTP was
at the discretion of the operator, so there was no consistent
dose, site of delivery, time period between cineangiographic
injections or recording of blood pressure and heart rate.
Thus, concentration response data were not gathered. Sec-
ond, because this was a retrospective analysis, treatment was
not randomized or compared to placebo or another agent.
Third, the patients studied are heterogeneous as to the
clinical condition for intervention, site of intervention and
devices used. The sample size is not adequate to identify
clinical settings where NTP is particularly effective or
ineffective in reversing no-reflow. Because of the study
population size, multivariate analysis may not accurately
ascertain if the NTP dose, delivery method, other medica-
tions and time from NTP dose to final angiogram are
independent predictors of changes in flow velocity. Further
data may be needed. The statistical results were identical
whether the data were analyzed per patient or per proce-
dure, because one patient had two procedures on two
separate grafts on two separate days. Despite these study
limitations, the data do suggest that a direct nitric oxide
donor such as NTP may be an effective treatment strategy
for no-reflow.
Conclusions. The data presented here support the hypoth-
esis that the direct nitric oxide donor NTP is a safe and
efficacious agent to treat no-reflow. It remains to be deter-
mined if the therapeutic application of nitric oxide biology
to no-reflow will result in lower cardiac enzyme levels or
survival benefit. Of importance, NTP in doses that do not
adversely affect blood pressure appears particularly effective
in the treatment of no-reflow in both vein grafts and native
coronary arteries undergoing percutaneous revascularization
procedures.
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